M. Hochstenbag

742 total citations
27 papers, 552 citations indexed

About

M. Hochstenbag is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, M. Hochstenbag has authored 27 papers receiving a total of 552 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pulmonary and Respiratory Medicine, 14 papers in Oncology and 7 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in M. Hochstenbag's work include Lung Cancer Research Studies (12 papers), Lung Cancer Diagnosis and Treatment (10 papers) and Lung Cancer Treatments and Mutations (9 papers). M. Hochstenbag is often cited by papers focused on Lung Cancer Research Studies (12 papers), Lung Cancer Diagnosis and Treatment (10 papers) and Lung Cancer Treatments and Mutations (9 papers). M. Hochstenbag collaborates with scholars based in Netherlands, United Kingdom and United States. M. Hochstenbag's co-authors include A. Twijnstra, Philippe Lambin, Madelon Pijls-Johannesma, J. T. Wilmink, Anita A.M. Botterweck, Anne‐Marie C. Dingemans, Wiel Geraedts, Cordula Pitz, Jean Simons and Dirk De Ruysscher and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Thorax.

In The Last Decade

M. Hochstenbag

26 papers receiving 548 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
M. Hochstenbag Netherlands	10	429	284	109	77	53	27	552
Edward Yu Canada	13	249 0.6×	143 0.5×	34 0.3×	71 0.9×	66 1.2×	27	434
H. Le Caer France	13	555 1.3×	523 1.8×	135 1.2×	41 0.5×	21 0.4×	49	819
Markus Glatzer Switzerland	13	199 0.5×	178 0.6×	71 0.7×	101 1.3×	47 0.9×	33	471
Brian De United States	12	198 0.5×	110 0.4×	47 0.4×	60 0.8×	56 1.1×	53	417
Annemarie F. Shepherd United States	15	328 0.8×	231 0.8×	39 0.4×	170 2.2×	92 1.7×	57	644
N. Bayman United Kingdom	15	753 1.8×	456 1.6×	89 0.8×	147 1.9×	112 2.1×	48	950
Philippe Lagarde France	8	208 0.5×	147 0.5×	40 0.4×	58 0.8×	28 0.5×	13	341
J. McAleese United Kingdom	15	282 0.7×	95 0.3×	65 0.6×	202 2.6×	132 2.5×	48	478
Yanqun Dong United States	10	145 0.3×	118 0.4×	55 0.5×	46 0.6×	42 0.8×	13	307
Sharma P. Riaz United Kingdom	8	310 0.7×	318 1.1×	120 1.1×	41 0.5×	9 0.2×	9	527

Countries citing papers authored by M. Hochstenbag

Since Specialization

Citations

This map shows the geographic impact of M. Hochstenbag's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Hochstenbag with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Hochstenbag more than expected).

Fields of papers citing papers by M. Hochstenbag

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Hochstenbag. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Hochstenbag. The network helps show where M. Hochstenbag may publish in the future.

Co-authorship network of co-authors of M. Hochstenbag

This figure shows the co-authorship network connecting the top 25 collaborators of M. Hochstenbag. A scholar is included among the top collaborators of M. Hochstenbag based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Hochstenbag. M. Hochstenbag is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mané-Damas, Marina, Peter Molenaar, Janneke G. J. Hoeijmakers, et al.. (2025). Myasthenia gravis with antibodies against the AChR, current knowledge on pathophysiology and an update on treatment strategies with special focus on targeting plasma cells. Autoimmunity Reviews. 24(10). 103875–103875. 1 indexed citations

Girard, Nicolas, Santiago Ponce Aix, S. Cedrés, et al.. (2023). Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial. ESMO Open. 8(3). 101576–101576. 19 indexed citations

Houben, Ruud, et al.. (2022). “Radiotherapy for thymic epithelial tumors: What is the optimal dose? A systematic review.”. Clinical and Translational Radiation Oncology. 34. 67–74. 3 indexed citations

Hendriks, Lizza, Jules L. Derks, Pieter E. Postmus, et al.. (2015). Single Organ Metastatic Disease, a New Prognostic Factor for Overall Survival (OS) in Stage IV Non-Small Cell Lung Cancer (NSCLC). Annals of Oncology. 26. i29–i29. 1 indexed citations

Hendriks, Lizza, Jules L. Derks, Pieter E. Postmus, et al.. (2015). Single organ metastatic disease and local disease status, prognostic factors for overall survival in stage IV non-small cell lung cancer: Results from a population-based study. European Journal of Cancer. 51(17). 2534–2544. 42 indexed citations

Hendriks, Lizza, M. Hochstenbag, Ulrich Lalji, & Anne‐Marie C. Dingemans. (2011). A pulmonary abscess, beware of lung cancer!. Respiratory Medicine CME. 4(4). 157–159. 3 indexed citations

Grutters, Janneke P.C., Manuela Joore, Erwin M. Wiegman, et al.. (2010). Health-related quality of life in patients surviving non-small cell lung cancer. Thorax. 65(10). 903–907. 80 indexed citations

Loon, J. Van, Dirk De Ruysscher, Rinus Wanders, et al.. (2009). 146PD SELECTIVE NODAL IRRADIATION ON BASIS OF 18FDG-PET SCANS IN LIMITED DISEASE SMALL CELL LUNG CANCER: A PROSPECTIVE STUDY. Lung Cancer. 64. S61–S61. 1 indexed citations

Ruysscher, Dirk De, Anita A.M. Botterweck, Miranda J.M. Dirx, et al.. (2008). Eligibility for concurrent chemotherapy and radiotherapy of locally advanced lung cancer patients: a prospective, population-based study. Annals of Oncology. 20(1). 98–102. 143 indexed citations

10.

Ruysscher, Dirk De, C. Dehing, Søren M. Bentzen, et al.. (2007). Maximal neutropenia during chemotherapy and radiotherapy is significantly associated with the development of acute radiation-induced dysphagia in lung cancer patients. Annals of Oncology. 18(5). 909–916. 40 indexed citations

11.

Ruysscher, Dirk De, Søren M. Bentzen, A. Minken, et al.. (2005). P-758 SER, a novel time factor predictive for long-term survival in patients with limited disease small cell lung cancer after combined chest radiotherapy and chemotherapy. Lung Cancer. 49. S318–S318. 1 indexed citations

12.

Baardwijk, Angela van, Dirk De Ruysscher, Robert‐Jan van Suylen, et al.. (2005). P-127 18-FDG uptake on PET-scan correlates with CA IX expression, asurrogate marker for hypoxia, in patients with NSCLC. Lung Cancer. 49. S148–S148. 2 indexed citations

13.

Ruysscher, Dirk De, S. Wanders, M. Hochstenbag, et al.. (2004). Selective mediastinal node irradiation on basis of the FDG-PET scan in patients with NSCLC is safe: results of a prospective clinical study. Radiotherapy and Oncology. 73. 1 indexed citations

14.

Bentzen, Søren M., Dirk De Ruysscher, S. Wanders, et al.. (2004). A novel time factor, the SER (Start of any treatment and the End of Radiotherapy), is predictive for local control and survival in a systematic overview of combined chest radiotherapy and chemotherapy for limited stage small cell lung cancer. Radiotherapy and Oncology. 73. 4 indexed citations

15.

Hochstenbag, M., A. Twijnstra, Paul A.M. Hofman, Emiel F.�M. Wouters, & G.P.M. ten Velde. (2003). MR-imaging of the brain of neurologic asymptomatic patients with large cell or adenocarcinoma of the lung. Does it influence prognosis and treatment?. Lung Cancer. 42(2). 189–193. 52 indexed citations

16.

Wel, Arjen van der, S. Nijsten, Søren M. Bentzen, et al.. (2003). 784 Increased tumor control probability (TCP) and radiation dose escalation by FDG-PET planning of patients with N2/N3 Mo non-small cell lung cancer (NSCLC): A modeling study. European Journal of Cancer Supplements. 1(5). S236–S236. 1 indexed citations

17.

Hochstenbag, M., et al.. (2000). Asymptomatic Brain Metastases (BM) in Small Cell Lung Cancer (SCLC): MR-imaging is Useful at Initial Diagnosis. Journal of Neuro-Oncology. 48(3). 243–248. 108 indexed citations

18.

Hochstenbag, M., A. Twijnstra, E.F.M. Wouters, & G.P.M. ten Velde. (1997). 850 Asymptomatic brain metastases (BM) in small cell lung cancer (SCLC): Is MRI useful at initial diagnosis?. Lung Cancer. 18. 219–219. 1 indexed citations

19.

Peters, Femke P., et al.. (1996). Abscess of the spleen. The Netherlands Journal of Medicine. 48(1). 11–14. 1 indexed citations

20.

Hochstenbag, M., Gabriël Snoep, Annemie M.W.J. Schols, et al.. (1996). Detection of bone marrow metastases in small cell lung cancer. Comparison of magnetic resonance imaging with standard methods. European Journal of Cancer. 32(5). 779–782. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact